Skip to Main Content

RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept
RTI International
  • About
    • Office Locations
    • Executive Leadership
    • Corporate Governance
    • Partner with Us
      • U.S. Government
      • Clients and Funding Agencies
      • Industry and Commercial Clients
      • Foundations and Associations
      • Bilateral Agencies and Multilateral Banks
      • Universities and Academic Research Institutions
      • Suppliers and Small Businesses
    • Commitment to Quality
      • RTI's Client Listening Program
    • Ethics and Human Research Protection
    • Living Our Mission
    • Veteran Opportunities at RTI

    About

  • Practice Areas
    • Health
      • Public Health and Well-Being
      • Health Care Transformation
      • Behavioral Health
      • Health Behavior Change
      • Precision Medicine
      • RTI Health Solutions (RTI-HS)
      • RTI Center for Community Health Evaluation and Economics Research
      • Health Equity
      • RTI Health Advance
    • Transformative Research Unit for Equity​
      • Equity Capacity Building Hub
      • Social and Economic Justice Research Collaborative
      • Narrative Research and Community Engagement Lab
    • Education and Workforce Development
      • Early Childhood
      • K-12 Education
      • Postsecondary Education
      • Career and Adult Education and Workforce Development
      • Education Policy, Systems, and Governance
      • Education Research Methodologies
      • Education Technologies
    • International Development
      • Energy for Development
      • Environment
      • Global Food Security, Agriculture, and Nutrition
      • Global Health
      • International Education
      • Monitoring, Evaluation, Research, Learning, and Adapting (MERLA)
      • Youth and Economic Opportunity
      • Building Resilience Against COVID-19 in Developing Countries
      • Water, Sanitation, and Hygiene (WASH)
      • RTI Center for Governance
    • Climate Change
      • Clean Energy Technology and Renewables
      • Climate Finance
      • Climate Justice and Equity
      • Climate Planning, Preparedness and Resilience
      • Climate Policy
      • Climate Vulnerability, Adaptation, and Mitigation
      • Economic Impacts of Climate Change
    • Water
      • Food-Energy-Water Nexus
      • Water Quality
      • WASH (Water, Sanitation, Hygiene)
      • Water Resources Management
    • Energy Research
      • Carbon Capture and Utilization
      • Biomass Conversion
      • Natural Gas
      • Energy Efficiency
      • Industrial Water
      • Syngas Processing
    • Environmental Sciences
      • Air Quality
      • RTI Center for Water Resources
      • Urban Sustainability
      • Toxics
      • Building Resiliency in the FEW Nexus
      • Climate Change Sciences and Analysis
      • Environmental Policy
      • Environmental Justice
      • Sustainable Materials & Waste Management Solutions
    • Justice Research and Policy
      • RTI Center for Community Safety and Crime Prevention
      • RTI Center for Policing Research and Investigative Science
      • Child Well-Being and Family Strengthening
      • RTI Center for Forensic Sciences
    • Food Security and Agriculture
      • Market Systems Strengthening
      • Food Safety
      • Food and Nutrition
      • Global Food Security, Agriculture, and Nutrition
      • Climate-Smart Agriculture
      • Agricultural Innovation
      • Obesity Prevention
    • Innovation Ecosystems
      • Innovation Advising
      • Innovation for Economic Growth
      • Innovation for Emerging and Developing Economies
      • Innovation for Organizations
      • Research, Technology, and Innovation Policy
      • Technology Acceleration
    • Military Support
      • Military Behavioral Health
      • Military Health and Human Performance
      • Military Sexual Assault, Harassment, and Domestic Violence Prevention
      • Wearable Sensor Technologies
      • Military Health System Transformation

    Practice Areas

  • Services + Capabilities
    • Surveys and Data Collection
      • Survey Design
      • Instrument Development
      • Survey Methodologies
      • Data Collection
      • Establishment Surveys
      • Health Registries
      • Data Analysis and Reporting
      • Research Operations Center
    • Statistics and Data Science
      • Survey Statistics
      • Environmental Statistics
      • Coordinating Centers for Multisite Studies
      • Analysis and Design of Complex Data
      • Biostatistics
      • RTI Center for Data Science
    • Evaluation, Assessment and Analysis
      • Evaluation Design and Execution
      • Advanced Qualitative, Quantitative, and Mixed Methods
      • Evaluation, Monitoring, and Assessment
      • Economic Analysis
      • Evaluating Communication Interventions and Campaigns
      • Evidence Synthesis for Policy and Practice
      • Risk Assessment and Prediction
    • Program Design and Implementation
      • Systems Strengthening and Scaling
      • Capacity Assessment and Building
      • Policy Reform Support
      • Curriculum and Teacher Professional Development
      • Interventions and Prevention Programs
      • Implementation Science
    • Digital Solutions for Social Impact
      • Human-Centered Design of Digital Solutions
      • Digital Product Development
      • Digital Communication Campaigns
      • Digital Data Analytics
    • Research Technologies
      • Survey Technologies
      • Data Management and Decision Support Systems
      • Geospatial Science, Technology, and Visualization
      • ICT for Limited-Resource Settings
      • Mobile Applications
      • Web Applications
      • Bioinformatics
      • Interactive Computing
    • Drug Discovery and Development
      • Medicinal Chemistry
      • Molecular Design and Cheminformatics
      • Behavioral Pharmacology
      • Drug Metabolism and Pharmacokinetics (DMPK)
      • In Vitro Pharmacology, Bioassay Development, and High-Throughput Screening (HTS)
      • Isotope Labeling
      • Regulatory Consulting and Support for Medical Products
    • Analytical Laboratory Sciences
      • Bioanalytical and Toxicology Research
      • Forensic Sciences
      • Physicochemical Characterizations
      • Metabolomics
      • Proficiency Testing and Reference Materials
      • Microbiology
      • Analytical Chemistry and Pharmaceutics
    • Engineering & Technology R&D
      • Biomedical Technologies
      • Decarbonization Sciences
      • Environmental Exposure & Protection
      • Materials & Environment
      • Sustainable Energy Solutions

    Services + Capabilities

  • Centers
    • RTI Center for Advanced Methods Development
    • RTI Center for Communication Science
      • Communication Research
      • Communication Design
      • Communication Delivery
    • RTI Center for Data Science
    • RTI Center for Education Services
      • Teaching and Learning
      • Education Leadership
      • Peer Learning Networks
      • Strategic Consulting
    • RTI Center for Forensic Sciences
    • RTI Center for Global Noncommunicable Diseases
      • Program Financing & Economics for NCDs
      • Health Systems Strengthening for NCDs
      • Communication Science and Behavior Change for NCDs
      • Implementation Science for NCDs
    • RTI GenOmics, Bioinformatics, and Translational Research Center
      • Disability Studies
      • Ethics
      • Newborn Screening
    • RTI Center for Water Resources
      • Water Resources Sectors
      • Water Resources Services
      • Water Resources Tools
    • RTI Center for Governance
    • RTI Global Gender Center
    • North Carolina Center for Optimizing Military Performance
    • NCCU-RTI Center for Applied Research in Environmental Sciences
    • RTI Center for Climate Solutions

    Centers

  • Impact
    • Newsroom
    • Insights Blog
    • Events
    • Publications
    • RTI Press
      • About the RTI Press
      • Instructions for Authors
      • RTI Press Collections
    • Projects
    • Global Reach
      • Asia
      • Eastern Europe and Central Asia
      • RTI International India
      • Africa
      • Middle East and North Africa (MENA)
      • Latin America and the Caribbean (LAC)

    Impact

  • Experts
    • Our Experts
    • In-Depth With Our Experts
    • Related News
    • Experts In the Media
    • RTI Fellow Program

    Experts

  • Emerging Issues
    • COVID-19 Research
    • Artificial Intelligence
    • Global Health Security
    • Cannabis Research
    • Opioid Research
      • Interventions for Opioid Use Disorders
      • Preventing Opioid Misuse and Overdose
      • Treating Opioid Use Disorders
    • Policing Research and Investigative Science
    • Drone Research and Application
    • E-cigarette Research
    • Zika Virus Research
    • Integrated Governance

    Emerging Issues

  • COVID-19 Research + Response
  • Global Reach
  • Insights Blog
  • Newsroom
  • RTI Press
  • Publications
  • Partner With Us
  • Careers
  • Facebook IconTwitter IconInstagram IconYouTube IconLinkedin Icon
  • Home
  • Impact
  • RTI Press
  • Is buprenorphine more effective and safer than other medical treatments for managing opioid withdrawal?

Is buprenorphine more effective and safer than other medical treatments for managing opioid withdrawal?

A Cochrane Review summary with commentary

By Ina Wallace, Meera Viswanathan.

August 2022 Open Access Peer Reviewed

DOI: 10.3768/rtipress.2022.rb.0031.2208

Check for Updates Download PDF
Wallace, I., & Viswanathan, M. (2022). Is buprenorphine more effective and safer than other medical treatments for managing opioid withdrawal? A Cochrane Review summary with commentary. RTI Press. RTI Press Research Brief No. RB-0031-2208 https://doi.org/10.3768/rtipress.2022.rb.0031.2208
Copy citation
Share
  • Share on Facebook
  • Share on Twitter
  • Share on Linkedin
  • Email
Key Points
  • Buprenorphine is similar in efficacy to methadone (i.e., severity of withdrawal, withdrawal treatment retention, withdrawal completion, and lack of adverse events) and is superior to both clonidine and lofexidine for managing opioid withdrawal.
  • The review authors did not reach conclusions about speed of tapering the dosing of buprenorphine.
  • The commentary authors indicate that ongoing research to examine contextual factors in medication for opioid withdrawal will elucidate what characteristics are linked to better outcomes.
  • The commentary suggests examining the efficacy of substitution treatment following medication for withdrawal.

Abstract

This paper summarizes the published Cochrane Review, “Buprenorphine for Managing Opioid Withdrawal,” by L. Gowing, R. Ali, J. M. White, & D. Mbewe (https://doi.org/10.1002/14651858.CD002025.pub5), and discusses it through a treatment policy and practice lens.

Creative Commons © 2023 RTI International. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Contents

  • Background
  • Methods
  • Search Methodology
  • Main Results
    • Comparison 1: Buprenorphine vs. Methadone for Managing Opioid Withdrawal (6 Studies)
      • Comparison 2: Buprenorphine vs. Clonidine or Lofexidine for Managing Opioid Withdrawal (14 Studies)
        • Comparison 3: Rapid vs. Slow Taper of Buprenorphine for Managing Opioid Withdrawal (7 Studies)
        • Cochrane Review Authors’ Conclusions
        • Commentary: Implications of the Cochrane Evidence for Policy and Practice
        • Commentary: Implications of the Cochrane Evidence for Research
        • Conclusions
        • Acknowledgments
        • References

        Is Buprenorphine More Effective and Safer Than Other Medical Treatments for Managing Opioid Withdrawal? A Cochrane Review Summary With Commentary

        By Ina F.WallaceMeeraViswanathan

        Background

        This paper summarizes the published Cochrane Review, “Buprenorphine for Managing Opioid Withdrawal,” by L. Gowing, R. Ali, J. M. White, & D. Mbewe,1 and discusses it through a treatment policy and practice lens.a This brief is one in a series prepared by RTI Press in agreement with the Cochrane Library/Wiley. These briefs summarize and add original commentary to research presented in Cochrane Reviews. This summary is based on a Cochrane Review previously published in the Cochrane Database of Systematic Reviews 2017, Issue 2, Art. No. CD002025, DOI: https://doi.org/10.1002/14651858.CD002025.pub5 (see https://www.cochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and Cochrane Database of Systematic Reviews should be consulted for the most recent version of the review.

        Recent statistics from the 2019 National Survey of Drug Use and Health2 reported that more than 1.5 million US adults aged 18 years or older had an opioid use disorder (OUD). The costs of untreated OUD in health care, criminal justice, and reduced productivity to individuals, families, and society have been estimated to be close to $150 billion per year.3 Treatment is critical to reducing the physical and economic burden of this disorder.

        Withdrawal from opioid dependence remains a required first step for many forms of long-term treatment such as residential rehabilitation and naltrexone maintenance. Medication in this context is designed to reduce the adverse effects of withdrawal and the intense craving for the substance so that individuals can focus on behavioral changes. Medical management for withdrawal is also a possible first step for subsequent treatment including medications for opioid use disorder (MOUD),4 previously known as “medication-assisted treatment.” MOUD includes counseling along with maintenance-dose medications of methadone, buprenorphine, or naltrexone.

        This Cochrane Review examined the evidence for efficacy and safety of one commonly used medication—buprenorphine—for managing opioid withdrawal in comparison with other medications or placebo. Gowing and colleagues1 rated the quality of the evidence for the primary outcomes using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, concluding that the strength of evidence ranged between very low and moderate, with the modal category low. We conducted a dual appraisal of the quality of the systematic review using AMSTAR2 (A MeaSurement Tool to Assess systematic Reviews)5 and concluded that we had moderate confidence in the Cochrane Review.

        Methods

        The study population included adolescents and adults who were opioid dependent and who received either buprenorphine or a comparison medication for managing withdrawal symptoms. The experimental intervention was buprenorphine; the included comparators were tapered doses of methadone; clonidine; lofexidine; symptomatic medications (e.g., nonopioid analgesics, benzodiazepines); placebo; or buprenorphine differing in amount, duration, or tapering rate. The primary outcomes of the review included intensity of withdrawal, duration of withdrawal treatment, and nature and incidence of harms; the secondary outcome was engagement in further treatment.

        Search Methodology

        The Cochrane Review authors searched for relevant randomized controlled trials (RCTs) of interventions using buprenorphine to manage opioid withdrawal in several databases up to December 2016. They also hand-searched reference lists of included literature, ongoing trials, and conference proceedings. The authors included non-English literature.

        Main Results

        The review included 27 RCTs. Of these studies, 14 were in the United States, 6 were in Europe, 2 each were in India and Iran, and 1 each were in Australia and Israel. The settings included 13 inpatient, 10 outpatient, 2 both inpatient and outpatient, 1 prison, and 1 residential therapeutic setting. Overall, the review included 3,048 participants, of whom approximately 70% were male, with a median age of 31 years.

        Comparison 1: Buprenorphine vs. Methadone for Managing Opioid Withdrawal (6 Studies)

        Meta-analysis was not possible for the outcome of intensity of withdrawal or adverse effects. However, the data from most individual studies testing this outcome indicated that buprenorphine and methadone were similar in withdrawal severity (4 studies). The 3 studies examining harms found no significant adverse events in either group.

        Meta-analysis suggested no difference between buprenorphine and methadone for the outcome of the average treatment duration (mean difference [MD]: 1.3 days, 95% confidence interval [CI]: -8.11 to 10.72; 2 studies) and no difference for treatment completion rates (risk ratio [RR]: 1.04, 95% CI: 0.91 to 1.20; 5 studies).

        Comparison 2: Buprenorphine vs. Clonidine or Lofexidine for Managing Opioid Withdrawal (14 Studies)

        The studies comparing either clonidine or lofexidine with buprenorphine found that patients treated with buprenorphine had less severe withdrawal during treatment (standardized mean difference (SMD) of withdrawal scores: -0.43, 95% CI: -0.58 to -0.28; 7 studies), stayed in treatment longer (SMD: 0.92, 95% CI: 0.57 to 1.27; 5 studies), and were more likely to complete treatment (RR: 1.59, 95% CI: 1.23 to 2.06; 12 studies). Although the authors did not detect a difference in harms, they acknowledged that in 3 studies, patients treated with clonidine were more likely to stop treatment because of adverse events than those treated with buprenorphine (RR: 0.20, 95% CI: 0.04 to 1.15).

        Comparison 3: Rapid vs. Slow Taper of Buprenorphine for Managing Opioid Withdrawal (7 Studies)

        In these studies, the analysis was conducted separately for inpatient and outpatient settings. Meta-analysis was possible only for the treatment completion outcome. For inpatient settings, the authors failed to find an effect of the rate of dose taper on treatment completion (RR: 1.00, 95% CI: 0.84 to 1.18; 2 studies). The authors also reported that they failed to find an effect of the rate of dose taper on treatment completion in outpatient settings (RR: 0.86, 95% CI: 0.44 to 1.70; 4 studies).

        Neither of the 2 inpatient studies examining the intensity of withdrawal found differences attributable to the rate of dose reduction. The 4 studies in outpatient settings that examined withdrawal severity reported mixed findings. For the outcome of duration of withdrawal treatment, the 1 inpatient study examining this outcome found similar treatment durations in the rapid and slower taper groups. In the 1 outpatient study reporting duration of withdrawal treatment, the frequency of clinic attendance was confounded with tapering. Only 1 inpatient study reported on harms, finding no difference between the treatment regimens. The 2 outpatient studies reported on adverse events; 1 found no adverse events, and 1 found no serious adverse events related to tapering.

        Cochrane Review Authors’ Conclusions

        Buprenorphine was similar in efficacy to methadone for managing opioid withdrawal in terms of severity of withdrawal, withdrawal treatment retention, withdrawal completion, and lack of adverse events. The Cochrane authors judged the quality of the evidence as low to moderate. Conversely, buprenorphine was superior to both clonidine and lofexidine for managing opioid withdrawal with no increase in adverse events; these treatment effects included fewer withdrawal symptoms, longer treatment duration, and greater likelihood of completing treatment in patients receiving buprenorphine. The authors rated the quality of this evidence as very low to moderate. The authors did not draw any firm conclusions regarding rapid versus slower reduction in dosing of buprenorphine, rating the quality of the evidence as very low to low.

        The authors recognized that a limitation of the review is the failure of the studies to report outcomes on the basis of sex, as males and females are known to respond differently to drug therapies.6 Lacking information regarding potential sex differences limits the ability of clinicians to select the best withdrawal treatment for an individual. The authors noted that further research is needed to establish the most effective doses, frequency, and duration of buprenorphine administration using objective criteria. The authors also briefly discussed buprenorphine as a substitute treatment for opioids. They indicated that because buprenorphine can be administered in an outpatient setting, it can be extended into substitution treatment for those patients who did not achieve abstinence. However, the authors cautioned that including both withdrawal management and substitution treatment in the same study would blur the distinctions between them.

        Commentary: Implications of the Cochrane Evidence for Policy and Practice

        Conclusions from the Cochrane Review indicate the efficacy of buprenorphine for managing opioid withdrawal. However, because of the high rates of reuse following opioid withdrawal, the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Treatment Improvement Panel (TIP) does not recommend short-term medically supervised withdrawal.7 If patients do want medication for withdrawal, SAMHSA’s TIP recommends providing psychosocial treatment along with medication for withdrawal. However, data from the Cochrane Systematic Review reported that psychotherapy was only an aftercare adjunct in one of the included studies. How widespread this practice is in medically supervised withdrawal is not known.

        Rather than using medication for withdrawal, the TIP panel recommends using substitution treatment that includes therapy with medication. This practice recommendation is facilitated by the US Drug Enforcement Administration waiver that permits health care providers to prescribe buprenorphine outside of opioid treatment programs after completing specialized training. However, as a recent report from the Pew Trust8 indicates, because the federal regulations limit the number of providers with waivers, many US counties do not have any eligible providers, leaving many individuals with OUD without access to this important treatment. A recent study indicates that out of 2,595 counties in 38 US states, 36% of urban counties and 32% of rural counties have an undersupply of buprenorphine providers.9 Moreover, despite the recommendation for MOUD, a study examining responses from more than 13,000 addiction facilities to the 2017 National Survey of Substance Abuse Treatment Services found that only 40% of the addiction treatment facilities offered any medication for OUD.10 This fact and the fact that the number of medical providers is limited leave many patients without viable options for medication treatment for OUD. Results from a second study11 that examined whether individuals with private medical insurance who were treated with buprenorphine received care adhering to American Society of Addiction Medicine12 guidelines were disappointing. Data from more than 38,000 individuals who received buprenorphine and were continuously enrolled in private insurance for 6 months indicated that most patients did not receive guideline-specified care. On average, patients completed only an average of 7.4 visits over the 6-month period. In addition, fewer than half of the patients filled buprenorphine prescriptions for at least 6 months.

        Commentary: Implications of the Cochrane Evidence for Research

        Based on the findings from the Cochrane Review and the policy landscape, we have suggestions for future research. Because the studies included in the Cochrane Review varied in dosing, frequency, and duration of buprenorphine administration, its authors could not determine the most effective dose or regimen. Systematically varying the dosing of buprenorphine, perhaps in a clinical trial, would make a real contribution to the field. Also critical are establishing the duration of buprenorphine withdrawal treatment and determining what personal characteristics are linked to better outcomes.

        Although the purpose of the Cochrane Review is not buprenorphine treatment for OUD, tying buprenorphine for withdrawal to buprenorphine for treatment of OUD may be helpful in light of the TIP recommendation cited previously.7 Given that many patients with OUD who are treated with buprenorphine (or the other medications) for managing withdrawal start using opioids again,6 assessing substitution treatment following withdrawal would provide a real-world examination of a common situation in treating patients with OUD.

        One investigation that bridges the gap is RECOVER,13 a cohort study that followed participants from one of two studies that examined long-acting buprenorphine, administered monthly for up to 12 months. The investigators found positive outcomes over the 12-month post-buprenorphine observation period. The study reported that half of the participants reported sustained abstinence over the 12-month follow-up period, and that 36% of the cohort indicated that they did not need any further treatment. Specifically, participants whose duration of buprenorphine was longer (either 6 to 11 months or 12 months) rather than shorter (3 to 5 months), who were female, or who were older had self-reported sustained abstinence at 12 months. Results of these studies suggest that substitution treatment lasting 12 months can lead to abstinence, the desired outcome of many who undertake withdrawal treatment.

        The HEALing (Helping to End Addiction Long-term) Communities Study,14,15 a multi-site cluster-RCT implemented in four states with the same protocol, is designed to examine the impact of a set of evidence—based practices that communities select to reduce opioid use disorder. Among the outcomes are expansion of MOUD (i.e., methadone, buprenorphine, naltrexone) by increasing demand for, access to, and retention for MOUD. This study will contribute to a greater understanding of the contextual factors affecting the use of buprenorphine and other evidence-based MOUD.

        Conclusions

        Buprenorphine is effective in managing opioid withdrawal without adverse effects, but unless buprenorphine is followed up with longer-term maintenance medication and psychosocial treatment, patients are liable to relapse. Data are still needed to examine for whom buprenorphine is most effective as a medication for withdrawal and to document the experience of moving from buprenorphine for managing opioid withdrawal to substitution treatment with buprenorphine. Addressing the limited number of eligible providers who can prescribe buprenorphine is critical for ensuring timely and appropriate management of opioid withdrawal as well as medical treatment for OUD.

        Acknowledgments

        We thank Kathy Lohr and Gary Zarkin for their careful and thoughtful review of this manuscript.

        The views expressed are those of the original summary article author and in no way represent the Cochrane Library or Wiley.

        References

        1Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev 2017;(2):CD002025. 10.1002/14651858.CD002025.pub5
        2Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. HHS Publication No. PEP20–07–01–001, NSDUH Series H-55). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2020. Available from: https://www.samhsa.gov/data/
        3Pew Charitable Trust. The high price of the opioid crisis, 2021. 2021 Aug. Available from: https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2021/the-high-price-of-the-opioid-crisis-2021
        4Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict 2019;28(2):55–62. 10.1111/ajad.1286230701615
        5Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008. 10.1136/bmj.j400828935701
        6Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009;48(3):143–57. 10.2165/00003088-200948030-0000119385708
        7Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63, Publication No. PEP21–02–01–002. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2021. Available from: https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf
        8Pew Charitable Trust. Policies should promote access to buprenorphine for opioid use disorder. 2021 May. https://www.pewtrusts.org/-/media/assets/2021/05/policiesshouldpromoteaccesstobuprenorphine_brief.pdf
        9Conway KP, Khoury D, Hilscher R, Aldridge AP, Parker SJ, Zarkin GA. Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018. Addict Sci Clin Pract 2022;17(1):5. 10.1186/s13722-021-00282-235101112
        10Mark T, Dowd WN, Council CL. Tracking the quality of addiction treatment over time and across states: using the federal government’s “signs” of higher quality. RTI Press Publication No. RR-0040–2007. Research Triangle Park (NC): RTI Press; 2020 Jul. 10.3768/rtipress.2020.rr.0040.2006
        11Mark TL, Hinde JM, Zarkin GA, Parish W, Kluckman M. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance. J Subst Abuse Treat 2020;116:108062. 10.1016/j.jsat.2020.10806232741503
        12Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med 2015;9(5):358–67. 10.1097/ADM.000000000000016626406300
        13Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H et al. Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study. J Addict Med 2020;14(5):e233–40. 10.1097/ADM.000000000000064732187112
        14Walsh SL, El-Bassel N, Jackson RD, Samet JH, Aggarwal M, Aldridge AP et al. ; HEALing Communities Study Consortium. The HEALing (Helping to End Addiction Long-term SM) Communities Study: protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug Alcohol Depend 2020;217:108335. 10.1016/j.drugalcdep.2020.10833533248391
        15Winhusen T, Walley A, Fanucchi LC, Hunt T, Lyons M, Lofwall M et al. The opioid-overdose reduction continuum of care approach (ORCCA): evidence-based practices in the HEALing communities study. Drug Alcohol Depend 2020;217:108325. 10.1016/j.drugalcdep.2020.10832533091842

        Click cover to download publication

        Contact

        To contact an author or seek permission to use copyrighted content, contact our editorial team

        • +1 919 541 6490
        • rtipress@rti.org

        Meet the Experts

        View All Experts

        Meera Viswanathan

        Ina F. Wallace

        Related Publications

        View All Press
        OCCASIONAL PAPER

        Bringing an equity-centered framework to research

        OCCASIONAL PAPER

        Culturally informed community engagement

        RESEARCH REPORT

        Substance misuse prevention program attendance

        RESEARCH BRIEF

        COVID-19’s impact on clinical research

        OCCASIONAL PAPER

        Social determinants of health

        OCCASIONAL PAPER

        Challenges facing CAHPS surveys and opportunities for modernization

        RESEARCH REPORT

        Artificially intelligent social risk adjustment

        OCCASIONAL PAPER

        The need for a diverse environmental justice workforce

        Recent Publications

        View All Press
        OCCASIONAL PAPER

        Bringing an equity-centered framework to research

        OCCASIONAL PAPER

        The Preschool Entitlement

        OCCASIONAL PAPER

        Culturally informed community engagement

        RESEARCH REPORT

        Substance misuse prevention program attendance

        RTI Logo
        Partner With Us
        • US Government
        • Commercial
        • Foundations & Associations
        • Multilateral Donors
        • Universities
        • Suppliers
        Site
        • Privacy Policy
        • Security Policy
        • Site Map
        • Terms of Use
        • Accessibility
        • Contact Us
        Contact Us
        Facebook Icon Twitter Icon Instagram Icon YouTube Icon Linkedin Icon
        delivering the promise of science
        for global good
        RTI Health Solutions RTI Innovation Advisors RTI Health Advance

        © 2023 RTI International. RTI International is a trade name of Research Triangle Institute. RTI and the RTI logo are U.S. registered trademarks of Research Triangle Institute.